BLOOD AND URINE POLYAMINES AS NEW DIAGNOSTIC MARKERS OF PROSTATE CANCER

Authors

  • S.P. Zaletok R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • O.О. Klenov R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • S.V. Gogol R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • V.V. Bentrad R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • Е.О. Stakhovsky R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • Yu.V. Vitruk R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine
  • B.O. Grechko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv, Ukraine

DOI:

https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7755

Keywords:

biochemical markers, polyamines, prostate cancer

Abstract

Prostate cancer (PC) is one of the prevalent malignancies in men of 50 and more years old. Currently, the commonly used marker for PC screening is PSA (prostate specific antigen). But PSA test is not enough sensitive and specific. Therefore, it is extremely important to find and develop new markers, in particular those that could be identified in the biological fluids of patients. Polyamines (PAs) deserve special attention as potential markers for differential diagnosis of PC. Aim: to specify level of spermine and other PA in blood and urine of the patients with PC, benign prostate tumors (BPT) and practically healthy men and evaluate efficacy of PA as extratumoral PC markers. Object and methods: level of PA (putrescine, spermidine, spermine and their acetylated forms) were measured in blood and urine of 120 PC patients, 30 BPT patients and 30 practically healthy men (control group). PA content was measured by HPLC and ELISA methods. Statistical data treatment was done using standard licensed computer programs STATISTICA 6.0, Microsoft Ехсеl, ANOVA «Statistica». Results: spermine level in the PC patients’ blood was shown to be significantly lower versus both BPT patients and practically healthy men. During the disease progress (from indolent to aggressive cancer), both blood spermidine level and spermidine/spermine ratio increase. In blood of PC patients, in contrary to BPT patients and healthy men, N1,N12-diacetylspermine was found. In PC patients urine, spermine level was 34 times lower than in healthy men and 13 times lower than in BPT patients. Conclusion: it is expedient to include PA measurement into the list of methods using to examine the patients with the prostate tumors. This would be useful to refine differential diagnosis of the prostate tumors and promote individualized therapy.

 

References

Stakhovsky EA, Fedorenko ZP, Vitruk YuV, et al. Prostate cancer screening. Clinical Oncology 2016; (1): 50–53 (in Russian).

Kurzanov AN, Strygin EA, Medvedev VL. Diagnostic and prognostic markers of prostate cancer. Modern problems of science and education 2016; (2). URL: http://www.science-education.ru/ru/article/view?id=24439 (in Russian).

Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277 (18): 1452–55.

Dani H and Loeb S. The role of biomarkers in undiagnosed men. Curr Opin Urol 2017; 27 (3): 210–16.

Won Tae Kim, Seok Joong Yun, Wun-Jae Kim. For physicians managing voiding dysfunction, improving the detection rate of early prostate cancer and discrimination from benign prosta­tic hyperplasia, in a molecular biomarker aspects. Int Neurourol 2019; 23 (1): 5–12.

Giskeødegård GF, Hansen AF, Bertilsson H, et al. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia. British J. Cancer 2015; 113 (12): 1712–9.

Zang X, Jones CM, Long TQ, et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. J Proteome Res 2014; 13 (7): 3444–54.

Roberts MJ, Richards RS, Chow CW, et al. Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: A preliminary investigation. Prostate Int 2017; 5 (4): 149–57.

Giskeødegård GF, Bertilsson H, Kirsten MS, et al. Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness. PLoS One 2013; 8 (4): e62375.

Tik-Hung Tsoi, Chi-Fai Chan, Wai-Lun Chan. Urinary polyamines: a pilot study on their roles as prostate cancer detection biomarkers. PLOS ONE 2016; 11 (9): e0162217.

Braadland PR, Giskeødegård GF, Sandsmark E, et al. Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy. Bri­tish J Cancer 2017; 117: 1656–64.

Vandergrift LA, Decelle EA, Kurth J, et al. Metabolomic Prediction of Human Prostate Cancer Aggressiveness:Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Scientific Reports 2018; 8: 4997–4809.

Esmaeili M, Tayari N, Scheenen T, et al. Simultaneous 18F-fluciclovinePositron Emission Tomography and Magnetic Resonance SpectroscopicImaging of Prostate Cancer. Frontiers in Oncology 2018; 8: 516.

Berdinsky NK, Zaletok SP. Polyamines and tumor growth. Naukova Dumka, Kyiv, 1987, 141 p. (in Russian).

Gerner E, Meyskens F. Polyamines and cancer: old molecules, new understanding. Nature reviews 2004; 4 (10): 781–92.

Zaletok SP. Polyamines — markers of tumor growth and targets for anticancer therapy. Thesis for the degree of Doctor of Biological Sciences (D. Biol. Sci.) speciality 14.01.07 — oncolo­gy. Kyiv, 2007. 37 p. (in Ukrainian).

Zaletok SP. The role of polyamines in carcinogenesis and tumor growth. Oncology. Selected lectures for students and doctors ed. VF Chekhun. Kyiv, 2010: 354–70 (in Ukrainian).

Kuniyasu S. The mechanisms by which polyamines accelerate tumor spread. J Exp Clin Cancer Res 2011; 30 (1): 95–9.

Schipper RG, Romijn JC, Cuijpers VMJI, et al. Polyamines and prostatic cancer. Biochemical Society Transactions 2003; 31 (2): 375–80.

van der Graaf M., Schipper RG, Oosterhof GO, et al. Proton MR spectroscopy of prostatic tissue focused on the detection of spermine, a possible biomarker of malignant behavior in prostate cancer. MAGMA 2000; 10 (3): 153–9.

Gerbaut L. Determination of erythrocytiс polyamines by reversed-phase liquid chromatography. Clin.Chem 1991; 37 (12): 2117–20.

http://www.elisakit.cc

Corbin JM, Ruiz-Echevarría MJ. One-carbon metabolism in prostate cancer: the role of androgen signaling. Int J Mol Sci 2016; 17 (8): 1208–34.

Huang W, Eickhoff JC, Ghomi FM, et al. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate 2015; 75 (11): 1150–59.

Shukla-Dave A, Castillo-Martin M, Chen M, et al. Ornithine decarboxylase is sufficient for prostate tumorigenesis via androgen receptor signaling. Am J Pathol 2016; 186 (12): 3131–45.

Cohen RJ, Fujiwara K, Holland JW, et al. Polyamines in prostatic epithelial cells and adenocarcinoma: the effects of androgen blockade. Prostate 2001; 49 (4): 278–84.

Kdadra M, Höckner S, Leung H, et al.Metabolomics biomarkers of prostate cancer: a systematic review. Diagnostics 2019; 9 (1): 21.

Downloads

Published

2019-09-19

How to Cite

Zaletok , S., Klenov , O., Gogol , S., Bentrad , V., Stakhovsky Е., Vitruk , Y., & Grechko , B. (2019). BLOOD AND URINE POLYAMINES AS NEW DIAGNOSTIC MARKERS OF PROSTATE CANCER. Oncology, 21(3), 219–223. https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7755

Issue

Vol. 21 No. 3 (2019): Oncology

Section

Original investigations